Bristol Sprycel Receives Broad Committee Support For Leukemia Indications
FDA’s Oncologic Drugs Advisory Committee votes unanimously in favor of dasatinib approval for all phases of Gleevec-resistant or intolerant CML.
FDA’s Oncologic Drugs Advisory Committee votes unanimously in favor of dasatinib approval for all phases of Gleevec-resistant or intolerant CML.